Novel Suicide Ligands of Tubulin Arrest Cancer Cells in S-Phase

Neoplasia

Volumn 1, Issue 6, 1999, Pages 498-507

  Davis, Ashley ^a,d   Jiang, Jian Dong ^b   Middleton, Kim M ^a,d   Wang, Yue ^b   Weisz, Imre ^b   Ling, Yi He ^c   Bekesi, J George ^b  

^a Cytoskeleton Inc   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Anti cancer; Anti tumor; Apoptosis; Novel; Tubulin

Indexed keywords

ANTINEOPLASTIC AGENT; LIGAND; TUBULIN;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE S PHASE; DRUG EFFECT; HUMAN; METABOLISM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; LIGANDS; S PHASE; TUBULIN; TUMOR CELLS, CULTURED;

EID: 0033287155     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900066     Document Type: Article

References (36)

1. Dumontet C, and Sikic B (1999). Mechanisms of action of and resistance to anti-tubulin agents: microtubule dynamics, drug transport and cell death. Review in J Clin Oncol 17, 1061-1070.
2. Rowinsky EK, and Donehower RC (1991). The clinical pharmacology and use of anti-microtubule agents in cancer chemotherapeutics. Pharmacol Ther 52, 35-84.
3. Wilson L (1970). Properties of colchicine binding protein from chick embryo brain. Interactions with vinca alkaloids and podophyllotoxin. Biochemistry 9, 4999-5007.
4. Wilson L, Creswell CR, and Chin D (1975). The mechanism of action of vinblastine. Binding of [acetyl-3H] vinblastine to embryonic chick brain tubulin and tubulin from sea urchin sperm tail outer doublet microtubules. Biochemistry 14, 5586-5592.
5. Malawista SE, Bensch KG, and Sato H (1968). Vinblastine and griseofulvin reversibly disrupt the living mitotic spindle. Science 160, 770-772.
6. George P, Journey LJ, and Goldstein MN (1965). Effect of vincristine on the fine structure of HeLa cells during mitosis. J Natl Cancer Inst 35, 355.
7. Schiff PB, and Horwitz SB (1979). Promotion of microtubule assembly in vitro by taxol. Nature 277, 665.
8. Schiff PB, Fant J, and Horwitz SB (1980). Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77, 1561.
9. Sandercock J, Parmar MK, and Torri V (1998). First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer 78, 1471-1478.
10. Miller KD, and Sledge GW, Jr (1999). Taxanes in the treatment of breast cancer: a prodigy comes of age. Cancer Invest 17, 121-136.
11. Jordan MA, and Wilson L (1998). Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10, 123-130.
12. Jiang JD, Wang Y, Roboz J, Strauchen J, Holland JF, and Bekesi JG (1998). Inhibition of microtubule assembly in tumor cells by 3-bromoacetylamino benzoylurea, a new cancericidal compound. Cancer Res 58, 2126-2133.
13. Jiang JD, Davis AS, Middleton KM, Ling Y-H, Perez-Soler R, Holland JF, and Bekesi JG (1998). 3-(lodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells. Cancer Res 58, 5389-5395.
14. Luduena RF, and Roach MC (1981). Interaction of tubulin with drugs and alkylating agents: 2. Effects of colchicine, podophyllotoxin and vinblastine on the alkylation of tubulin. Biochemistry 20, 444-4450.
15. Halder S, Chintapalli J, and Croce CM (1996). Taxol-induced bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56, 1253-1255.
16. Ling YH, Consoli U, Tomos C, Andreeff M, Perez-Soler R (1998). Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol. Int J Cancer 75, 925-932.
17. Halder S, Basu A, and Croce CM (1997). Bcl-2 is the guardian of microtubule integrity. Cancer Res 57, 229-233.
18. Blagosklonny MV, et al. (1997). Raf1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57, 130-135.
19. Yang J, et al. (1997). Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275, 1129-1132.
20. Kluck RM, Bossy-Wetzel E, Green DR, and Newmeyer DD (1997). The release of cytochrome c from mitochondria: a primary site for bcl-2 regulation of apoptosis. Science 275, 1132-1136.
21. Costantini P, Petronilli V, Colona R, and Bernardi P (1995). On the effects of paraquat on isolated mitochondria. Evidence that paraquat causes opening of the cyclosporin A-sensitive permeability transition pore synergistically with nitric oxide. Toxicology 99, 77-88.
22. Marchetti P, et al. (1996). Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 183, 1155-1160.
23. Zamzami N, et al. (1996). Mitochondria control of nuclear apoptosis. J Exp Med 183, 1533-1544.
24. Evtodienko YV, et al. (1996). Microtubule-active drugs suppress the closure of the permeability transition pore in tumour mitochondria. FEBS Lett 393, 86-88.
25. Okada CY, and Rechsteiner M (1982). Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles. Cell 29, 33-41.
26. Brown JM, and Wouters BG (1999). Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59, 1391-1399.
27. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, and Bhalla K (1997). Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 11, 253-257.
28. Dey S, Ramachandra M, Pastan I, Gottesman MM, and Ambudkar SV (1997). Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 94, 10594-10599.
29. Parker C, Lakshmi MS, Piura B, and Sherbet GV (1994). Metastasis associated mts1 gene expression correlates with increased p53 detection in B16 murine melanoma. DNA Cell Biol 13, 343-351.
30. Marklund U, Larsson N, Gradin HM, Brattsand G, and Gullberg M (1996). Oncoprotein 18 is a phosphorylation responsive regulator of microtubule dynamics. EMBO J 15, 5290-5298.
31. Sherbet GV, and Lakshmi MS (1998). S100A4 (MTS1) calcium binding protein in cancer growth, invasion and metastasis. Anticancer Res 18, 2415-2422.
32. Trielli MO, Andreassen PR, Lacroix FB, and Margolis RL (1996). Differential taxol-dependent arrest of transformed and non-transformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells. JCB 135, 689-700.
33. Shan B, et al. (1999). Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug resistant tumors. Proc Natl Acad Sci USA 96 (10), 5686-5690.
34. Banjeree R, et al. (1992). Productive non-lytic HIV-1 replication in a newly established human leukemia cell line. Proc Natl Acad Sci USA 89, 996-1000.
35. Bekesi JG, et al. (1995). Translocation of cytoplasmic antigen markers in a biphenotypic cell line derived from a patient with myelodysplasia syndrome. Mol Cell Differ 3, 111-123.
36. Davis AS, and Middleton KM (1998). Lyophilized tubulins. USPTO application no. 09/310,981. Patent pending.